Marimastat Reduces Tumor Growth in Gastric Cancer
Author Information
Author(s): Watson S A, Morris T M, Collins H M, Bawden L J, Hawkins K, Bone E A
Primary Institution: Cancer Studies Unit Department of Surgery, Queen's Medical Centre, Nottingham, UK
Hypothesis
Does marimastat affect tumor growth and circulating tumor antigen levels in gastric cancer?
Conclusion
Marimastat significantly reduced tumor growth but did not directly affect circulating CEA levels.
Supporting Evidence
- Marimastat reduced tumor growth rate by 48%.
- Median survival increased from 19 to 30 days with marimastat treatment.
- Circulating CEA levels were linearly related to tumor weight.
Takeaway
Marimastat is a drug that helps shrink tumors in stomach cancer, but it doesn't change certain blood markers that doctors usually check.
Methodology
Mice with human gastric tumors were treated with marimastat, and tumor growth and CEA levels were measured.
Participant Demographics
Mice bearing the human gastric tumor, MGLVA1.
Statistical Information
P-Value
P = 0.0005; P = 0.0001; P = 0.7
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website